Vancouver, British Columbia - June 20, 2012 (Investorideas.com Newswire) Sirona Biochem Corp. ( TSX-V: SBM
, OTC: SRBCF, Frankfurt: ZSB), announced today results from a
preclinical study of its sodium glucose transporter (SGLT) inhibitor in
monkeys. When administered orally, Sirona Biochem’s SGLT inhibitor,
SBM-TFC-039, triggered glucosuria in a dose-dependent manner. In
addition, the glucosuria effect was robust for the full 24 hours
studied.
"At the recent American Diabetes Association meeting in
Philadelphia, it was apparent that SGLT inhibitors are a potentially
ground-breaking treatment for Type 2 diabetes," said Dr. Howard Verrico,
President and CEO of Sirona Biochem. "Preclinical results of our SGLT
inhibitor, SBM-TFC-039, in multiple species have consistently
demonstrated its efficacy and we are exploring data that may differentiate SBM-TFC-039 from the other SGLT inhibitors in development," he added.
SBM-TFC-039 is an SGLT inhibitor drug candidate for Type 2
diabetes. In the kidneys, SGLT inhibitors reduce the reabsorption of
glucose into the bloodstream by eliminating excess glucose into the
urine.
SBM-TFC-039 has been tested acutely and chronically in a rodent
diabetic model, in addition to the latest study in primates. In those
tests, SBM-TFC-039 has consistently demonstrated a glucose-lowering
effect in a dose-dependent manner.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes
therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging
agents for cosmetic use, and biological ingredients. The company
utilizes a proprietary chemistry technique to improve pharmaceutical
properties of carbohydrate-based molecules. For more information visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone: 604.282.6065
Email: jjang@sironabiochem.com
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date of release of the relevant information, unless explicitly stated
otherwise. Actual results, performance or achievement could differ
materially from those expressed in, or implied by, Sirona Biochem’s
forward-looking statements due to the risks and uncertainties inherent
in Sirona Biochem’s business including, without limitation, statements
about: the progress and timing of its clinical trials; difficulties or
delays in development, testing, obtaining regulatory approval, producing
and marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and validity
of patent protection for its products; competition from other
pharmaceutical or biotechnology companies; and its ability to obtain
additional financing to support its operations. Sirona Biochem does not
assume any obligation to update any forward-looking statements except as
required by law.
Published at the Investorideas.com Newswire
Disclaimer http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com was not compensated for this news report
Wednesday, June 20, 2012
Tuesday, June 19, 2012
Biotech Stock News Alert;Aethlon Medical (OTC: AEMD) Announces Notice of Allowance of U.S. Patent Application
SAN DIEGO - June 19, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD),
the pioneer in
developing selective therapeutic filtration devices to address
infectious disease, cancer and other life-threatening conditions,
announced today that the U.S. Patent and Trademark Office (USPTO) has
given the Company a Notice of Allowance for U.S. Patent Application No.
12/282152 entitled "Extracorporeal Removal of Microvesicular Particles."
The patent grants Aethlon the exclusive right to remove immune
suppressive microvesicular particles, which include but are not limited
to exosomes, from the circulation of treated patients. The patent
describes a method to bind and capture immune suppressive microvesicular
particles from blood with a medical filtration device containing single
or multiple affinity agents, which can include antibodies, aptamers,
beads, lectins, proteins, or other compounds that adhere to
microvesicles. The USPTO further notified the Company that it has
calculated a Patent Term Adjustment of 452 days on the Notice of
Allowance.
"This patent allowance provides a cornerstone that reinforces our
opportunity to establish a dominant market position in the therapeutic
targeting of immunosuppressive exosomes," stated Jim Joyce, Chairman and
CEO at Aethlon Medical. The Aethlon Hemopurifier�, which is a
first-in-class device being advanced in Hepatitis C care, has
demonstrated the ability to capture a broad-spectrum of immune
suppressive exosomes underlying cancer. A therapy that could inhibit
exosome proliferation would fulfill a major unmet medical need as
corresponding drug therapies have yet to emerge.
In cancer, exosomes have recently emerged to become a vital therapeutic target as they play an instrumental role in promoting tumor progression by inducing programmed cell death of anticancer immune cells. As a result of inhibiting the immune response, exosomes increase the proliferation and spread of many forms of cancer. The particles also seed the spread of tumor metastasis, promote angiogenesis (essential for tumor survival and growth), increase tumor aggressiveness, and contribute to anti-cancer drug resistance.
Circulating microvesicles or exosomes have also been discovered to have immunosuppressive roles in infectious disease and may accelerate the pathogenesis of other disease conditions as they have been reported to induce or amplify inflammatory and pathological conditions including, cardiovascular disease, hypertension, neurodegenerative disorders, diabetes, and rheumatic diseases. Beyond its cancer and infectious disease treatment initiatives, Aethlon is studying the deleterious role of exosomes in sepsis through a contract with the Defense Advanced Research Projects Agency (DARPA).
In addition to being known as exosomes, microvesicles have been referred to as epididimosomes, argosomes, exosome-like vesicles, microparticles, promininosomes, prostasomes, dexosomes, texosomes, dex, tex, archeosomes and oncosomes.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs
"This patent allowance provides a cornerstone that reinforces our
opportunity to establish a dominant market position in the therapeutic
targeting of immunosuppressive exosomes," stated Jim Joyce, Chairman and
CEO at Aethlon Medical. The Aethlon Hemopurifier�, which is a
first-in-class device being advanced in Hepatitis C care, has
demonstrated the ability to capture a broad-spectrum of immune
suppressive exosomes underlying cancer. A therapy that could inhibit
exosome proliferation would fulfill a major unmet medical need as
corresponding drug therapies have yet to emerge.In cancer, exosomes have recently emerged to become a vital therapeutic target as they play an instrumental role in promoting tumor progression by inducing programmed cell death of anticancer immune cells. As a result of inhibiting the immune response, exosomes increase the proliferation and spread of many forms of cancer. The particles also seed the spread of tumor metastasis, promote angiogenesis (essential for tumor survival and growth), increase tumor aggressiveness, and contribute to anti-cancer drug resistance.
Circulating microvesicles or exosomes have also been discovered to have immunosuppressive roles in infectious disease and may accelerate the pathogenesis of other disease conditions as they have been reported to induce or amplify inflammatory and pathological conditions including, cardiovascular disease, hypertension, neurodegenerative disorders, diabetes, and rheumatic diseases. Beyond its cancer and infectious disease treatment initiatives, Aethlon is studying the deleterious role of exosomes in sepsis through a contract with the Defense Advanced Research Projects Agency (DARPA).
In addition to being known as exosomes, microvesicles have been referred to as epididimosomes, argosomes, exosome-like vesicles, microparticles, promininosomes, prostasomes, dexosomes, texosomes, dex, tex, archeosomes and oncosomes.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs
Gold and Mining Stocks; Gold Bullion (TSX-V: GBB) announces additional positive drill data update
VANCOUVER - June 19, 2012 (Investorideas.com Mining stocks Newswire) - Gold Bullion Development Corp. (TSXV: GBB, OTC PINK: GBBFF)
(the "Company" or "Gold Bullion") is pleased to announce additional
drill results from several holes located throughout the mineralized area
of the Granada Gold Property. The subject property is located along the
prolific Cadillac trend in northwestern Quebec , 5 km south of the city
of Rouyn-Noranda.
Of the 17 holes, 14 reported significant gold mineralization with hole GR-11-389 at 0.53 g/t Au over 95.0 metres from 72.0 metres to 167.0 metres confirming continuity of the mineralized package near surface inclusive of three discrete higher-grade zones. Hole GR-11-389 was drilled in the Southeast direction to confirm mineralization and assist in the exact positioning of the NNE fault displacing the mineralized blocks between sections.
These assay results are from the 2011 drill program and continue to demonstrate low-grade, high tonnage, near surface intersections while confirming specific high-grade zone at depth with thickness and grade suitable for underground mining.
Highlights include GR-11-260 with 4.87 g/t Au over 3.89 metres at depth while near surface hole GR-11-272 reported 0.39 g/t Au over 129.0 metres from 112.0 metres to 241.0 metres. Gold Bullion's CEO Frank Basa is very encouraged by results that consistently demonstrate the presence of widespread significant gold mineralization on the Granada property. Further details on the mineralized holes inclusive of substantive drill data are summarized in the table below.
Only three holes, GR-11-364, GR-11-251 and E-11-06 did not cut
significant mineralization as follows: GR-11-364 was northwest and too
short to intersect the zone while both GR-11-251 and E-11-06 were
intended to test the Eastern extension and may not have been suitably
located to cut the zones due to the NE shift of mineralized blocks
caused by the NNE Faults.
Additional assay results are pending and will be released as they become available.
Claude Duplessis , Eng. is acting as the qualified person (QP) for Gold Bullion Development Corp. in compliance with National Instrument 43-101 and has reviewed the technical contents of this press release.
Investor Relations Agreement Terminated
The Company also announces it has provided 30 days' notice to terminate, effective July 15, 2012 , the Investor Relations Agreement dated September 10, 2009 wherein Progressive IR Consultants Corp. of Vancouver , British Columbia, was engaged to provide investor relations services to the Company.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture-listed junior natural resource company focusing on the exploration and development of its Granada Property near Rouyn-Noranda, Quebec. Additional information on the company's Granada gold property is available by visiting their website at www.GoldBullionDevelopmentCorp.com and on SEDAR.com.
Frank J. Basa, P.Eng.
President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
Of the 17 holes, 14 reported significant gold mineralization with hole GR-11-389 at 0.53 g/t Au over 95.0 metres from 72.0 metres to 167.0 metres confirming continuity of the mineralized package near surface inclusive of three discrete higher-grade zones. Hole GR-11-389 was drilled in the Southeast direction to confirm mineralization and assist in the exact positioning of the NNE fault displacing the mineralized blocks between sections.
These assay results are from the 2011 drill program and continue to demonstrate low-grade, high tonnage, near surface intersections while confirming specific high-grade zone at depth with thickness and grade suitable for underground mining.
Highlights include GR-11-260 with 4.87 g/t Au over 3.89 metres at depth while near surface hole GR-11-272 reported 0.39 g/t Au over 129.0 metres from 112.0 metres to 241.0 metres. Gold Bullion's CEO Frank Basa is very encouraged by results that consistently demonstrate the presence of widespread significant gold mineralization on the Granada property. Further details on the mineralized holes inclusive of substantive drill data are summarized in the table below.
Only three holes, GR-11-364, GR-11-251 and E-11-06 did not cut
significant mineralization as follows: GR-11-364 was northwest and too
short to intersect the zone while both GR-11-251 and E-11-06 were
intended to test the Eastern extension and may not have been suitably
located to cut the zones due to the NE shift of mineralized blocks
caused by the NNE Faults.Additional assay results are pending and will be released as they become available.
Claude Duplessis , Eng. is acting as the qualified person (QP) for Gold Bullion Development Corp. in compliance with National Instrument 43-101 and has reviewed the technical contents of this press release.
Investor Relations Agreement Terminated
The Company also announces it has provided 30 days' notice to terminate, effective July 15, 2012 , the Investor Relations Agreement dated September 10, 2009 wherein Progressive IR Consultants Corp. of Vancouver , British Columbia, was engaged to provide investor relations services to the Company.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture-listed junior natural resource company focusing on the exploration and development of its Granada Property near Rouyn-Noranda, Quebec. Additional information on the company's Granada gold property is available by visiting their website at www.GoldBullionDevelopmentCorp.com and on SEDAR.com.
Frank J. Basa, P.Eng.
President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
Visit the GBB showcase profile at Investorideas.com
Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.
Disclosure, Disclaimer/ Investorideas.com
is paid by GBB to publish news and distribute content through
Investordeas.com Newswire and its syndicated partners and blogs (five
hundred per month)Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.
Monday, June 18, 2012
Solar Stock Investor News; First Solar (NASDAQ:FSLR) Sees Morning High of $15.17
New York, NY - June 18, 2012 (Investorideas.com renewable
energy/green newswire) Investorideas.com news staff: Investorideas.com, a
leader in renewable energy stock research for independent investors,
issues a trading alert for solar stock First Solar, Inc. (NASDAQ:FSLR), spiking as high as $15.17 on the day, now trading at $14.69, up 0.74 (5.30%) 10:39AM EDT on over 4 Million shares.
First Solar has a 52 week range of $ 11.43 - 142.22. Several analysts including our solar stocks expert J. Peter Lynch have called possible bottom in solar stocks. Solar stocks including First Solar showed investors some green in last week's trading.
Last week the Company announced it will design, construct and maintain two utility-scale solar photovoltaic (PV) power projects totaling 159 megawattsAC (MW) for AGL Energy Limited as part of Australia's Solar Flagships Program. AGL was selected as the successful proponent in the solar PV category of the program and will receive federal and state government funding to help deliver on its commitment to greater investment in renewable electricity generation.
About First Solar, Inc.
First Solar is a leading global provider of comprehensive photovoltaic (PV) solar systems which use its advanced thin-film modules. The company's integrated power plant solutions deliver an economically attractive alternative to fossil-fuel electricity generation today. From raw material sourcing through end-of-life module collection and recycling, First Solar's renewable energy systems protect and enhance the environment. For more information about First Solar, please visit www.firstsolar.com.
Research more solar stocks on global stock exchanges - and up to 1400 renewable energy stocks at Investorideas.com http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com on Google Plus
Follow Renewable Energy Stocks onFacebook.com
http://www.facebook.com/renewableenergystocks
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more. Join: http://www.investorideas.com/membership/
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com
contact:
800.665.0411
First Solar has a 52 week range of $ 11.43 - 142.22. Several analysts including our solar stocks expert J. Peter Lynch have called possible bottom in solar stocks. Solar stocks including First Solar showed investors some green in last week's trading.
Last week the Company announced it will design, construct and maintain two utility-scale solar photovoltaic (PV) power projects totaling 159 megawattsAC (MW) for AGL Energy Limited as part of Australia's Solar Flagships Program. AGL was selected as the successful proponent in the solar PV category of the program and will receive federal and state government funding to help deliver on its commitment to greater investment in renewable electricity generation.
About First Solar, Inc. First Solar is a leading global provider of comprehensive photovoltaic (PV) solar systems which use its advanced thin-film modules. The company's integrated power plant solutions deliver an economically attractive alternative to fossil-fuel electricity generation today. From raw material sourcing through end-of-life module collection and recycling, First Solar's renewable energy systems protect and enhance the environment. For more information about First Solar, please visit www.firstsolar.com.
Research more solar stocks on global stock exchanges - and up to 1400 renewable energy stocks at Investorideas.com http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com on Google Plus
Follow Renewable Energy Stocks onFacebook.com
http://www.facebook.com/renewableenergystocks
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more. Join: http://www.investorideas.com/membership/
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com
contact:
800.665.0411
Gold Is Still CHEAP-. Silver Is Even CHEAPER - Eric Muschinski of the Gold Investment Letter
June 18, 2012 (Investorideas.com Mining Newswire) Eric Muschinski,
editor of the Gold Investment Letter issues the following commentary for
investors following gold and mining stocks. Eric Muschinski has been
recommending gold and silver accumulation since 2003 to his clients.
http://www.goldinvestmentletter.com/
Millions will be made in gold and silver stocks in the coming years of this bull market. Will you participate and make a killing with our subscribers? My name is Eric Muschinski and I am the editor of the Gold Investment Letter. I welcome you to benefit from our research, contacts, and passion for profiting in the markets NOW. We will guide you to sit tight and buy near bottoms, while staying disciplined by taking profits to protect your principal and ensure maximizing your gains in this volatile gold bull market. I have been recommending to my clients and accumulating gold and silver since 2003. Frankly, the best is yet to come as the bull market enters its inevitable frenzy stage and gold/silver stocks make savvy investors rich (or richer!)!
Let the Gold Investment Letter help you maximize and protect your profits into the frenzy stage of this gold bull market.
Why the Gold Investment Letter? Read our bio here. The Gold Investment Letter will give you unbiased (we do not get paid by the companies we recommend), specific, and actionable recommendations on our favorite picks. We tend to prefer listed stocks that are not heavily promoted and will provide ample liquidity for our subscribers. So, register for our free e-letter, get our top pick, and get to know us at no risk to you!
Subscribe to receive our top junior gold stock pick and bi-weekly updates on the market from " The Nation's Most Trusted Voice for Investment GOLD ."
For an update on our top Graphite stock click here!
http://www.goldinvestmentletter.com/zenyatta-buying-opportunity/
© 2012 Gold Investment Letter. All rights reserved
The editor of Gold Investment Letter, Eric Muschinski, who has been recommending gold and silver accumulation since 2003 to his clients, is Founder and CEO of Phenom Ventures LLC, President and Co-Founder of Investor Media Inc., and Co-Founder and Managing Member of Diadem Media Group. Eric has over 15 years of diverse experience in the capital markets. Initially as a general securities broker, and later becoming recognized as a specialist assisting the needs of high-net-worth investors, Eric focused his practice on alternative investments, including venture capital, private equity, and alternative investment management, exclusively for accredited investors and institutions.
Prior to Waveland Capital Partners where he worked from 2006-2011, Eric was Vice President and Co-Founder of GunnAllen Venture Partners where he worked with financial advisors to enhance their practice by understanding offerings and incorporating late-stage private equity and venture capital into their client services. Prior to GunnAllen, Eric served in the Private Client Group with McDonald Investments Inc., and another boutique investment bank headquartered in Chicago.
Eric specializes in alternative investment management, gold equities, hedge fund investing, private equity, equity trading/investing, gold/silver investing, business development, lead generation, and raising capital. Eric also educates sophisticated investors on how to invest in hedge funds and gain access and understanding into the burgeoning secondary market of pre-ipo private company investing. Eric studied Business Economics and Psychology at the University of Wisconsin-Whitewater while interning at both Piper Jaffray and Merrill Lynch.
875 North Michigan Avenue, Suite 3100 • Chicago, IL 60611 • See disclaimer at:
http://www.goldinvestmentletter.com/about/
Eric Muschinski, Editor
Gold Investment Letter
eric@investormediainc.com
Published at the Investorideas.com mining stocks newswire
Publish your news on the Investorideas.com Newswire
Disclaimer: Investorideas.com sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp. The opinions expressed in this newsletter are not the opinions of Investorideas.com – Investor Ideas is a publisher of this content only .
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
FACT: Gold Is Still CHEAP. Silver Is Even CHEAPER
Eric Muschinskihttp://www.goldinvestmentletter.com/
Millions will be made in gold and silver stocks in the coming years of this bull market. Will you participate and make a killing with our subscribers? My name is Eric Muschinski and I am the editor of the Gold Investment Letter. I welcome you to benefit from our research, contacts, and passion for profiting in the markets NOW. We will guide you to sit tight and buy near bottoms, while staying disciplined by taking profits to protect your principal and ensure maximizing your gains in this volatile gold bull market. I have been recommending to my clients and accumulating gold and silver since 2003. Frankly, the best is yet to come as the bull market enters its inevitable frenzy stage and gold/silver stocks make savvy investors rich (or richer!)!
Let the Gold Investment Letter help you maximize and protect your profits into the frenzy stage of this gold bull market.
Why the Gold Investment Letter? Read our bio here. The Gold Investment Letter will give you unbiased (we do not get paid by the companies we recommend), specific, and actionable recommendations on our favorite picks. We tend to prefer listed stocks that are not heavily promoted and will provide ample liquidity for our subscribers. So, register for our free e-letter, get our top pick, and get to know us at no risk to you!
Subscribe to receive our top junior gold stock pick and bi-weekly updates on the market from " The Nation's Most Trusted Voice for Investment GOLD ."For an update on our top Graphite stock click here!
http://www.goldinvestmentletter.com/zenyatta-buying-opportunity/
© 2012 Gold Investment Letter. All rights reserved
The editor of Gold Investment Letter, Eric Muschinski, who has been recommending gold and silver accumulation since 2003 to his clients, is Founder and CEO of Phenom Ventures LLC, President and Co-Founder of Investor Media Inc., and Co-Founder and Managing Member of Diadem Media Group. Eric has over 15 years of diverse experience in the capital markets. Initially as a general securities broker, and later becoming recognized as a specialist assisting the needs of high-net-worth investors, Eric focused his practice on alternative investments, including venture capital, private equity, and alternative investment management, exclusively for accredited investors and institutions.
Prior to Waveland Capital Partners where he worked from 2006-2011, Eric was Vice President and Co-Founder of GunnAllen Venture Partners where he worked with financial advisors to enhance their practice by understanding offerings and incorporating late-stage private equity and venture capital into their client services. Prior to GunnAllen, Eric served in the Private Client Group with McDonald Investments Inc., and another boutique investment bank headquartered in Chicago.
Eric specializes in alternative investment management, gold equities, hedge fund investing, private equity, equity trading/investing, gold/silver investing, business development, lead generation, and raising capital. Eric also educates sophisticated investors on how to invest in hedge funds and gain access and understanding into the burgeoning secondary market of pre-ipo private company investing. Eric studied Business Economics and Psychology at the University of Wisconsin-Whitewater while interning at both Piper Jaffray and Merrill Lynch.
875 North Michigan Avenue, Suite 3100 • Chicago, IL 60611 • See disclaimer at:
http://www.goldinvestmentletter.com/about/
Eric Muschinski, Editor
Gold Investment Letter
eric@investormediainc.com
Published at the Investorideas.com mining stocks newswire
Publish your news on the Investorideas.com Newswire
Disclaimer: Investorideas.com sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp. The opinions expressed in this newsletter are not the opinions of Investorideas.com – Investor Ideas is a publisher of this content only .
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Thursday, June 14, 2012
Solar Stocks Alert; JA Solar Holdings (JASO) Bounces on News of Share Buy Back
New York, NY - June 14, 2012 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in renewable energy stock research for independent investors, issues a solar stock alert for JA Solar Holdings Co., Ltd. (NasdaqGS:JASO), trading up at $1.09, gaining $ 0.16 or (17.20%) 10:18AM EDT on over 4 Million shares, with a high of $1.16.
The Company today reported that its board of directors has approved a share repurchase program, effective immediately, that authorizes JA Solar to repurchase up to a US$100 million worth of its issued and outstanding American Depositary Shares ("ADSs") prior to September 30, 2012.
Research more cleantech stocks on global stock exchanges - and up to 1400 at Investorideas.com renewable energy stocks stock directory
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter
Follow Investorideas.com on Facebook
Follow Investorideas.com on Google Plus
Follow Renewable Energy Stocks on Facebook.com
Sign Up: Get Free investor news and stock alerts
Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more.
Disclaimer/ Disclosure : Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp Investorideas.com was not compensated for this report and does not hold a position in the stock
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com
contact:
800.665.0411
The Company today reported that its board of directors has approved a share repurchase program, effective immediately, that authorizes JA Solar to repurchase up to a US$100 million worth of its issued and outstanding American Depositary Shares ("ADSs") prior to September 30, 2012.
Research more cleantech stocks on global stock exchanges - and up to 1400 at Investorideas.com renewable energy stocks stock directory About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter
Follow Investorideas.com on Facebook
Follow Investorideas.com on Google Plus
Follow Renewable Energy Stocks on Facebook.com
Sign Up: Get Free investor news and stock alerts
Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more.
Disclaimer/ Disclosure : Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp Investorideas.com was not compensated for this report and does not hold a position in the stock
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com
contact:
800.665.0411
Wednesday, June 13, 2012
Pharma Stocks Dominate NASDAQ Top Percentage Gainers: ARNA, DNDN, HZMP, RPTP
New York, New York - June 13, 2012 (InvestorIdeas.com Newswire)
Investorideas.com, an investor research portal specializing in sector
research including biotech and pharma stocks, issues an alert on the top
percentage gainers for morning trading June13th. Four of the five top
gainers, ARNA, DNDN, HZMP, RPTP, are pharma stocks.
Arena Pharmaceuticals, Inc. (NasdaqGS: ARNA) is trading up at $8.30, gaining $0.42(5.33%) 11:08AM EDT on over 25 Million shares with a high of $8.65. Commentary was issued on the stock yesterday on its participation in the anti obesity market.
Dendreon Corp. (NasdaqGS DNDN) is trading at $6.66, up 0.41(6.56%) 11:11AM EDT, with a high of $6.98 on volume of over 8 million shares.
Horizon Pharma, Inc. (NasdaqGM: HZNP) is trading up at $4.58, gaining 0.37(8.79%) 11:13AM EDT with a morning high of $4.73 on over 1 Million shares.
Raptor Pharmaceuticals Corp. (NasdaqGM :RPTP) is up, trading at $5.8350, jumping $0.3950 or (7.26%) 11:14AM EDT with a high of $6.15 in earlier trading on volume of over 2.7 Million shares. The Company reported yesterday that Christopher M. Starr, Ph.D., Chief Executive Officer of Raptor, will present an overview of the Company at the 2012 Wells Fargo Securities Healthcare Conference in Boston, MA at the InterContinental Hotel. Raptor's Presentation will take place on Tuesday, June 19, 2012 beginning at 3:30 p.m ET.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and stock alerts at Investorideas.com
Research biotech and pharma stocks at the Biotech stocks Directory
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
Arena Pharmaceuticals, Inc. (NasdaqGS: ARNA) is trading up at $8.30, gaining $0.42(5.33%) 11:08AM EDT on over 25 Million shares with a high of $8.65. Commentary was issued on the stock yesterday on its participation in the anti obesity market.
Dendreon Corp. (NasdaqGS DNDN) is trading at $6.66, up 0.41(6.56%) 11:11AM EDT, with a high of $6.98 on volume of over 8 million shares.
Horizon Pharma, Inc. (NasdaqGM: HZNP) is trading up at $4.58, gaining 0.37(8.79%) 11:13AM EDT with a morning high of $4.73 on over 1 Million shares.
Raptor Pharmaceuticals Corp. (NasdaqGM :RPTP) is up, trading at $5.8350, jumping $0.3950 or (7.26%) 11:14AM EDT with a high of $6.15 in earlier trading on volume of over 2.7 Million shares. The Company reported yesterday that Christopher M. Starr, Ph.D., Chief Executive Officer of Raptor, will present an overview of the Company at the 2012 Wells Fargo Securities Healthcare Conference in Boston, MA at the InterContinental Hotel. Raptor's Presentation will take place on Tuesday, June 19, 2012 beginning at 3:30 p.m ET.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and stock alerts at Investorideas.com
Research biotech and pharma stocks at the Biotech stocks Directory
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
Medical Device Stock to Watch; Aethlon Medical (AEMD) Chairman and CEO Discusses Melanoma Exosomes
New York, New York - June 13, 2012 (Investorideas.com Newswire)
Investorideas.com, an investor research portal specializing in sector
research including biotech and pharma stocks, issues a news alert and
company snapshot for Aethlon Medical (OTCBB:AEMD)
, following news issued yesterday by the Company . Featuring commentary
authored by Chairman and CEO, Jim Joyce on "Cancer Research Discovery -
Melanoma Exosomes Fuel Organ Metastasis".
Aethlon Medical (OTCBB:AEMD) develops medical devices to address needs in cancer, infectious disease, and other life-threatening conditions.
"Our first research into cancer-secreted exosomes was driven by the curiosity that exosomes seemed to carry a unique high mannose signature that is found on the surface of glycoproteins that coat infectious viral pathogens. This signature happened to be the targeted binding site of the affinity agent immobilized in our Hemopurifier®, and provides the basis for our ability to selectively capture HCV, HIV, and a broad-spectrum of other viruses. In well-studied viruses such as HIV, we knew that surface glycoproteins can shed to trigger apoptosis or programmed cell death of immune cells. Therefore, it made sense to us that exosomes might have these same immunosuppressive properties. However, at the time we initiated our research, the medical community consensus was that exosomes were nothing more than cellular trash bags with no meaningful biologic function. In fact, there were only a handful of researchers with exosome focused research programs. This is no longer the case. Many cancer research institutes are now pursuing exosome driven initiatives as cancer-secreted exosomes have since been verified to play a significant role in the invasion of the immune system in cancer patients. Additionally, researchers now understand how exosomes contribute to the development of tumor angiogenesis as a mechanism for cancer to survive. The harmful role of exosomes is also being identified in other life threatening conditions, including sepsis, a disease we are studying under contract with the Defense Advanced Research Projects Agency (DARPA).
To date, we have demonstrated the ability to capture exosomes underlying a variety of cancers. As related to the discoveries by the Weill Cornell team, we fortuitously disclosed in September of 2010 that our Aethlon Hemopurifier® was able to capture exosomes derived from individuals with metastatic melanoma in a pre-clinical study. At present, we are fully focused on participating in a response to a new DARPA contract opportunity, expanding our HCV treatment studies, and preparing the resubmission of a investigational device exemption to FDA. Once these objectives have been advanced, we plan to discuss a potential melanoma treatment study that a U.S. based cancer research institute has proposed to conduct as a result of the Weill Cornell discoveries."
Full News:
http://www.investorideas.com/CO/AEMD/news/2012/06121.asp
About Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and stock alerts at Investorideas.com
Research biotech stocks at the Biotech stocks Directory
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure investorideas.com is compensated by AEMD for news publication at Investorideas.com and syndicated partners: four thousand eight hundred fifty for six months
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
Aethlon Medical (OTCBB:AEMD) develops medical devices to address needs in cancer, infectious disease, and other life-threatening conditions.
"Our first research into cancer-secreted exosomes was driven by the curiosity that exosomes seemed to carry a unique high mannose signature that is found on the surface of glycoproteins that coat infectious viral pathogens. This signature happened to be the targeted binding site of the affinity agent immobilized in our Hemopurifier®, and provides the basis for our ability to selectively capture HCV, HIV, and a broad-spectrum of other viruses. In well-studied viruses such as HIV, we knew that surface glycoproteins can shed to trigger apoptosis or programmed cell death of immune cells. Therefore, it made sense to us that exosomes might have these same immunosuppressive properties. However, at the time we initiated our research, the medical community consensus was that exosomes were nothing more than cellular trash bags with no meaningful biologic function. In fact, there were only a handful of researchers with exosome focused research programs. This is no longer the case. Many cancer research institutes are now pursuing exosome driven initiatives as cancer-secreted exosomes have since been verified to play a significant role in the invasion of the immune system in cancer patients. Additionally, researchers now understand how exosomes contribute to the development of tumor angiogenesis as a mechanism for cancer to survive. The harmful role of exosomes is also being identified in other life threatening conditions, including sepsis, a disease we are studying under contract with the Defense Advanced Research Projects Agency (DARPA).
To date, we have demonstrated the ability to capture exosomes underlying a variety of cancers. As related to the discoveries by the Weill Cornell team, we fortuitously disclosed in September of 2010 that our Aethlon Hemopurifier® was able to capture exosomes derived from individuals with metastatic melanoma in a pre-clinical study. At present, we are fully focused on participating in a response to a new DARPA contract opportunity, expanding our HCV treatment studies, and preparing the resubmission of a investigational device exemption to FDA. Once these objectives have been advanced, we plan to discuss a potential melanoma treatment study that a U.S. based cancer research institute has proposed to conduct as a result of the Weill Cornell discoveries."
Full News:
http://www.investorideas.com/CO/AEMD/news/2012/06121.asp
About Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and stock alerts at Investorideas.com
Research biotech stocks at the Biotech stocks Directory
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure investorideas.com is compensated by AEMD for news publication at Investorideas.com and syndicated partners: four thousand eight hundred fifty for six months
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
Tuesday, June 12, 2012
Battery Stocks Investor Alert: A123 Systems (NasdaqGS: AONE) Charges Renewable Energy Stocks Sector; High of $1.67
New York, NY - June 12, 2012 (Investorideas.com renewable
energy/green newswire) Investorideas.com, a leader in renewable energy
stock research for independent investors, issues an investor alert for
A123 Systems, Inc. (NasdaqGS: AONE)
spiking on volume of over 25 Million shares with a high of $1.67. The
stock is currently trading at $1.43, up 0.39 or (37.49%).
The Company today introduced Nanophosphate EXT(TM), a new lithium ion battery technology capable of operating at extreme temperatures without requiring thermal management. Nanophosphate EXT is designed to significantly reduce or eliminate the need for heating or cooling systems, which is expected to create sizeable new opportunities within the transportation and telecommunications markets, among others.
A123 Systems, Inc. (NasdaqGS: AONE) is a leading developer and manufacturer of advanced lithium-ion batteries and energy storage systems
for transportation, electric grid and commercial applications. The
company's proprietary Nanophosphate(R) technology is built on novel
nanoscale materials initially developed at the Massachusetts Institute
of Technology and is designed to deliver high power and energy density,
increased safety and extended life. A123 leverages breakthrough
technology, high-quality manufacturing and expert systems integration
capabilities to deliver innovative solutions that enable customers to
bring next-generation products to market. For additional information
please visit www.a123systems.com.
Research more cleantech stocks on global stock exchanges - and up to 1400 at Investorideas.com renewable energy stocks stock directory
About Investorideas.com - a leader in cleantech investor research
www.Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter
Follow Investorideas.com on Facebook
Follow Investorideas.com on Google Plus
Follow Renewable Energy Stocks on Facebook.com
Sign Up: Get Free investor news and stock alerts
Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more.
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp Investorideas.com was not compensated for this report and does not hold a position in the stock
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com
contact:
800.665.0411
The Company today introduced Nanophosphate EXT(TM), a new lithium ion battery technology capable of operating at extreme temperatures without requiring thermal management. Nanophosphate EXT is designed to significantly reduce or eliminate the need for heating or cooling systems, which is expected to create sizeable new opportunities within the transportation and telecommunications markets, among others.
A123 Systems, Inc. (NasdaqGS: AONE) is a leading developer and manufacturer of advanced lithium-ion batteries and energy storage systems
for transportation, electric grid and commercial applications. The
company's proprietary Nanophosphate(R) technology is built on novel
nanoscale materials initially developed at the Massachusetts Institute
of Technology and is designed to deliver high power and energy density,
increased safety and extended life. A123 leverages breakthrough
technology, high-quality manufacturing and expert systems integration
capabilities to deliver innovative solutions that enable customers to
bring next-generation products to market. For additional information
please visit www.a123systems.com. Research more cleantech stocks on global stock exchanges - and up to 1400 at Investorideas.com renewable energy stocks stock directory
About Investorideas.com - a leader in cleantech investor research
www.Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter
Follow Investorideas.com on Facebook
Follow Investorideas.com on Google Plus
Follow Renewable Energy Stocks on Facebook.com
Sign Up: Get Free investor news and stock alerts
Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more.
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp Investorideas.com was not compensated for this report and does not hold a position in the stock
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com
contact:
800.665.0411
Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Note: Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis
SAN DIEGO - June 12, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Last week, Medical News Today reported on a cancer research discovery
that reinforces the potential importance of our therapeutic endeavors.
For more than a century, cancer researchers have understood that certain
forms of cancer only spread to specific, preferred organs. However, the
mechanism underlying the spread of organ specific metastasis (the "soil
and seed" theory of 1889) had remained unknown. Based on new findings
published and now available online in the journal Nature, researchers
have identified that circulating cancer-secreted particles known as
"exosomes" play a significant role in fueling the metastatic invasion of
preferred organs. The paper concludes that exosomes offer promise for
new therapeutic directions in the metastatic process.
We applaud and appreciate this ground breaking research as our Hemopurifier� has been validated to capture the form of cancer-secreted exosomes referenced in the publication. The same Hemopurifier� that we have been advancing with promising results in the treatment of hepatitis c (HCV) infected individuals.
In the study, researchers were interested to see if exosomes budding from melanoma actually participated in the course of the cancer. The answer was yes, and to a great extent. The researchers identified that melanoma cancer cells released "exosome" vesicles (microscopic particles like "bubbles" that are filled with many different molecules such as proteins and nucleic acids) that travel to the bone, liver, lung and brain. This cellular material fuses with targeted organs and establishes the environment to spread tumor cells. The researchers also reported that cancer-secreted exosomes triggered inflammation, promoted leaky blood vessels and educated bone marrow progenitor cells to participate in the metastatic cascade. The discoveries were led by a team from the Weill Cornell Medical College, Memorial Sloan-Kettering Cancer Center, with collaborative support from researchers at MD Anderson Cancer Center, Lawrence Berkeley National Laboratory, the National Cancer Institute, and the US National Institutes of Health.
Dr. Hector Peinado, the lead author of the study was quoted to say: "If, in the future, we were able to find a way to control the education of bone marrow cells, as well as the release and content of tumor exosomes in cancer patients, we would be able to curtail and reduce the spread of cancer, and improve the patient's quality of life and survival." At present, I am not aware of another therapeutic strategy beyond our Hemopurifier� that offers to inhibit or eliminate the presence of cancer-secreted exosomes.
The Weill-Cornell researchers also identified that exosome protein levels in circulation predicted disease stage, prognosis, and survival in subjects with metastatic disease. When they compared circulating exosomes taken from patients with different stages of melanoma, they found that stage IV patients displayed much higher exosome protein levels as compared with earlier stage melanoma patients. If disease had not yet metastasized, exosomes were not present in circulation. The researchers also noted that stage IV patients with a lower presence of exosomes tended to have longer survival than stage IV patients with higher exosome protein content. Again, reinforcing the therapeutic potential of a device that could inhibit or eliminate exosomes from circulation.
Our first research into cancer-secreted exosomes was driven by the curiosity that exosomes seemed to carry a unique high mannose signature that is found on the surface of glycoproteins that coat infectious viral pathogens. This signature happened to be the targeted binding site of the affinity agent immobilized in our Hemopurifier�, and provides the basis for our ability to selectively capture HCV, HIV, and a broad-spectrum of other viruses. In well-studied viruses such as HIV, we knew that surface glycoproteins can shed to trigger apoptosis or programmed cell death of immune cells. Therefore, it made sense to us that exosomes might have these same immunosuppressive properties. However, at the time we initiated our research, the medical community consensus was that exosomes were nothing more than cellular trash bags with no meaningful biologic function. In fact, there were only a handful of researchers with exosome focused research programs. This is no longer the case. Many cancer research institutes are now pursuing exosome driven initiatives as cancer-secreted exosomes have since been verified to play a significant role in the invasion of the immune system in cancer patients. Additionally, researchers now understand how exosomes contribute to the development of tumor angiogenesis as a mechanism for cancer to survive. The harmful role of exosomes is also being identified in other life threatening conditions, including sepsis, a disease we are studying under contract with the Defense Advanced Research Projects Agency (DARPA).
To date, we have demonstrated the ability to capture exosomes underlying a variety of cancers. As related to the discoveries by the Weill Cornell team, we fortuitously disclosed in September of 2010 that our Aethlon Hemopurifier� was able to capture exosomes derived from individuals with metastatic melanoma in a pre-clinical study. At present, we are fully focused on participating in a response to a new DARPA contract opportunity, expanding our HCV treatment studies, and preparing the resubmission of a investigational device exemption to FDA. Once these objectives have been advanced, we plan to discuss a potential melanoma treatment study that a U.S. based cancer research institute has proposed to conduct as a result of the Weill Cornell discoveries.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
All financial disclosures, anticipated revenue recognition amounts and other information related to the financial results and operations of the Company set forth above are unaudited and are subject to year-end audit adjustments and footnote disclosures.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs
Last week, Medical News Today reported on a cancer research discovery
that reinforces the potential importance of our therapeutic endeavors.
For more than a century, cancer researchers have understood that certain
forms of cancer only spread to specific, preferred organs. However, the
mechanism underlying the spread of organ specific metastasis (the "soil
and seed" theory of 1889) had remained unknown. Based on new findings
published and now available online in the journal Nature, researchers
have identified that circulating cancer-secreted particles known as
"exosomes" play a significant role in fueling the metastatic invasion of
preferred organs. The paper concludes that exosomes offer promise for
new therapeutic directions in the metastatic process.We applaud and appreciate this ground breaking research as our Hemopurifier� has been validated to capture the form of cancer-secreted exosomes referenced in the publication. The same Hemopurifier� that we have been advancing with promising results in the treatment of hepatitis c (HCV) infected individuals.
In the study, researchers were interested to see if exosomes budding from melanoma actually participated in the course of the cancer. The answer was yes, and to a great extent. The researchers identified that melanoma cancer cells released "exosome" vesicles (microscopic particles like "bubbles" that are filled with many different molecules such as proteins and nucleic acids) that travel to the bone, liver, lung and brain. This cellular material fuses with targeted organs and establishes the environment to spread tumor cells. The researchers also reported that cancer-secreted exosomes triggered inflammation, promoted leaky blood vessels and educated bone marrow progenitor cells to participate in the metastatic cascade. The discoveries were led by a team from the Weill Cornell Medical College, Memorial Sloan-Kettering Cancer Center, with collaborative support from researchers at MD Anderson Cancer Center, Lawrence Berkeley National Laboratory, the National Cancer Institute, and the US National Institutes of Health.
Dr. Hector Peinado, the lead author of the study was quoted to say: "If, in the future, we were able to find a way to control the education of bone marrow cells, as well as the release and content of tumor exosomes in cancer patients, we would be able to curtail and reduce the spread of cancer, and improve the patient's quality of life and survival." At present, I am not aware of another therapeutic strategy beyond our Hemopurifier� that offers to inhibit or eliminate the presence of cancer-secreted exosomes.
The Weill-Cornell researchers also identified that exosome protein levels in circulation predicted disease stage, prognosis, and survival in subjects with metastatic disease. When they compared circulating exosomes taken from patients with different stages of melanoma, they found that stage IV patients displayed much higher exosome protein levels as compared with earlier stage melanoma patients. If disease had not yet metastasized, exosomes were not present in circulation. The researchers also noted that stage IV patients with a lower presence of exosomes tended to have longer survival than stage IV patients with higher exosome protein content. Again, reinforcing the therapeutic potential of a device that could inhibit or eliminate exosomes from circulation.
Our first research into cancer-secreted exosomes was driven by the curiosity that exosomes seemed to carry a unique high mannose signature that is found on the surface of glycoproteins that coat infectious viral pathogens. This signature happened to be the targeted binding site of the affinity agent immobilized in our Hemopurifier�, and provides the basis for our ability to selectively capture HCV, HIV, and a broad-spectrum of other viruses. In well-studied viruses such as HIV, we knew that surface glycoproteins can shed to trigger apoptosis or programmed cell death of immune cells. Therefore, it made sense to us that exosomes might have these same immunosuppressive properties. However, at the time we initiated our research, the medical community consensus was that exosomes were nothing more than cellular trash bags with no meaningful biologic function. In fact, there were only a handful of researchers with exosome focused research programs. This is no longer the case. Many cancer research institutes are now pursuing exosome driven initiatives as cancer-secreted exosomes have since been verified to play a significant role in the invasion of the immune system in cancer patients. Additionally, researchers now understand how exosomes contribute to the development of tumor angiogenesis as a mechanism for cancer to survive. The harmful role of exosomes is also being identified in other life threatening conditions, including sepsis, a disease we are studying under contract with the Defense Advanced Research Projects Agency (DARPA).
To date, we have demonstrated the ability to capture exosomes underlying a variety of cancers. As related to the discoveries by the Weill Cornell team, we fortuitously disclosed in September of 2010 that our Aethlon Hemopurifier� was able to capture exosomes derived from individuals with metastatic melanoma in a pre-clinical study. At present, we are fully focused on participating in a response to a new DARPA contract opportunity, expanding our HCV treatment studies, and preparing the resubmission of a investigational device exemption to FDA. Once these objectives have been advanced, we plan to discuss a potential melanoma treatment study that a U.S. based cancer research institute has proposed to conduct as a result of the Weill Cornell discoveries.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
All financial disclosures, anticipated revenue recognition amounts and other information related to the financial results and operations of the Company set forth above are unaudited and are subject to year-end audit adjustments and footnote disclosures.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs
Monday, June 11, 2012
LOHAS Stock Mannatech (NASDAQ: MTEX) Gains over 18%
New York, NY - June 11, 2012 - www.InvestorIdeas.com, a global
investor research portal for independent investors, reports on trading
for LOHAS (Lifestyle of Health and Sustainability) stock Mannatech (NASDAQ: MTEX), trading up at$6.01, gaining 0.95 (18.81%) 2:42PM EDT on light volume.
About Mannatech
Mannatech, Incorporated, develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. Mannatech is dedicated to its platform of Social Entrepreneurship based on the foundation of promoting, aiding and optimizing nutrition where it is needed most around the world. Mannatech’s proprietary products are available through independent sales Associates around the globe including the United States, Canada, South Africa, Namibia, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech Republic, the Republic of Korea and Mexico. For more information, visit Mannatech.com.
Learn more about Lohas (Lifestyle of Health and Sustainability) stocks at Investorideas.com
http://www.investorideas.com/LOHAS-Investing/
Sign up for the free investor news and stock alerts in leading sectors! http://www.investorideas.com/ Resources/Newsletter.asp
Join Investor Ideas - Research LOHAS stocks, energy stocks, mining, agriculture stocks, cloud computing stocks and more…
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only eleven stock directories in leading sectors including renewable energy, water and energy stocks.
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - Investorideas.com
About Mannatech Mannatech, Incorporated, develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. Mannatech is dedicated to its platform of Social Entrepreneurship based on the foundation of promoting, aiding and optimizing nutrition where it is needed most around the world. Mannatech’s proprietary products are available through independent sales Associates around the globe including the United States, Canada, South Africa, Namibia, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech Republic, the Republic of Korea and Mexico. For more information, visit Mannatech.com.
http://www.investorideas.com/LOHAS-Investing/
Sign up for the free investor news and stock alerts in leading sectors! http://www.investorideas.com/ Resources/Newsletter.asp
Join Investor Ideas - Research LOHAS stocks, energy stocks, mining, agriculture stocks, cloud computing stocks and more…
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only eleven stock directories in leading sectors including renewable energy, water and energy stocks.
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - Investorideas.com
TSX Oil and Gas Stock Horn Petroleum (TSX.V: HRN) Gains over 13%
New York, NY - June 11, 2012 - www.InvestorIdeas.com, a leader in sector research for independent investors issues a trading snapshot for TSX oil and gas stock, Horn Petroleum Corporation (TSX.V:HRN).
The stock is trading at $1.52, gaining 0.18 or (13.43%) 10:33AM EDT on
volume of over 440,000 shares. The stock has a morning high of $1.57.
Last week the Company announced the commencement of drilling operations on the Shabeel North well in Puntland, Somalia, the second well in the current drilling campaign. On Friday the Company reported it closed a $15 Million Private Placement. The Company sold on a non-brokered private placement basis an aggregate of 18.75 million units at a price of $0.80 per unit for gross proceeds of $15 million.
Horn Petroleum Corporation is a Canadian oil and gas company with
assets in Puntland, Somalia. The Corporation holds a 60% interest and
operatorship in the Dharoor and Nugaal blocks encompassing a Jurassic
Rift Basin on trend and analogous to the large oil fields in Yemen
Research Oil and Gas Stocks at Investorideas.com stock directory – includes TSX, OTC, NASDAQ, NYSE and global stock exchanges.
Research natural gas stocks at Investorideas.com directory
Sign up for the free investor news and stock alerts at Investorideas.com
About InvestorIdeas.com:
www.InvestorIdeas.com is a leader in investor stock research, with a focus on energy and water. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, oil and gas stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure Investorideas.com is long shares and was not compensated
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Investorideas.com 800 665 0411
Last week the Company announced the commencement of drilling operations on the Shabeel North well in Puntland, Somalia, the second well in the current drilling campaign. On Friday the Company reported it closed a $15 Million Private Placement. The Company sold on a non-brokered private placement basis an aggregate of 18.75 million units at a price of $0.80 per unit for gross proceeds of $15 million.
Horn Petroleum Corporation is a Canadian oil and gas company with
assets in Puntland, Somalia. The Corporation holds a 60% interest and
operatorship in the Dharoor and Nugaal blocks encompassing a Jurassic
Rift Basin on trend and analogous to the large oil fields in YemenResearch Oil and Gas Stocks at Investorideas.com stock directory – includes TSX, OTC, NASDAQ, NYSE and global stock exchanges.
Research natural gas stocks at Investorideas.com directory
Sign up for the free investor news and stock alerts at Investorideas.com
About InvestorIdeas.com:
www.InvestorIdeas.com is a leader in investor stock research, with a focus on energy and water. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, oil and gas stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure Investorideas.com is long shares and was not compensated
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Investorideas.com 800 665 0411
Portfolio and General Market Update -"Red Flags STILL Flying" - J. Peter Lynch
New York, New York - June 11, 2012 - Investorideas.com, a leader
in cleantech stock research, issues an updated column from well
known solar analyst, J. Peter Lynch , commenting on solar stocks and the
general markets.
Solar Stocks Commentary with J Peter Lynch at Investorideas.com
Read other articles from Mr. Lynch, Exclusively at InvestorIdeas.com
http://www.investorideas.com/PL/
Current Portfolio Status
Since early March (3-6-2012) our solar portfolio has been out of the market and 100% in cash.
The total return of the 2012 portfolio has been a gain of 18.98% with a total holding time of 7 weeks. Once our indicators told us to exit our stocks, we moved quickly and sold our positions.
Remember that the HARDEST THING for investors to do is know when to sell. There is so much emotion, fear of missing out and general over all doubt. This is exactly why you have to set specific, non-emotional prices to exit if things do not go right. You cannot allow your emotions to get involved and take over your thinking.
Trust in your system and follow it regardless of what you think "should happen". Once you try to impose your will on your portfolio you will stop paying attention to what is most important - "what is" NOT what you think it should be.
General Market Comments - Red Flags Flying, move to the sidelines.
As I said in my last article (5-20-2012) the market has triggered
most of my technical indicators starting in late April all the way up to
the most recent major indicator turning to SELL on Tuesday the 17 th of
May.
At this point the general market is what I would characterize as being in a RED FLAG environment in which I would move to the sidelines and wait for the market to run its course. In addition, we have entered the markets seasonably UNFAVORABLE season (May - Oct) which historically has been a terrible time to be invested. In addition, all of my technical indicators have signaled sell signals.
Keep in mind that there is NO WAY to know if this is the end of a short correction or the beginning of a longer market downtrend - all we can do is listen to our indicators and follow their lead. When we do that we eliminate "emotion" i.e. what we THINK should be happening from our investment equation and follow our time proven indicators that show us what is REALLY happening regardless of our opinion.
Solar Stocks Status
Since solar stocks as a whole have much higher volatility (beta) than the general markets we have seen then fall much further than the market in general - this is not unexpected and is the reason our indicators told us to exit ALL our solar stocks in early March 2012.
The industry and the solar marketplace are currently undergoing extreme turmoil with negatives everywhere and nothing positive in sight:
With all of these negatives and depressed stocks is there any good
news that investors can take to heart and maybe see the beginnings of a
light (sunlight) at the end of the tunnel?
Well there are a couple of things we can look at and say that they may be the early beginnings of some good news and maybe the first sign of a buying opportunity:
Background Analysis Notes
Keep in mind that there are two basic types of equity (stock) analysis. Below are a brief description of each and its primary purpose:
Fundamental Analysis - this is the analysis of the fundamental financial condition of a company to identify which stocks you may want to buy when the timing is right. This form of analysis will give you NO indication of the best time to buy a stock or sell a stock.
Technical Analysis - this form of analysis will tell you "when" to buy a stock and when to sell the stock. It will do this by showing you (in chart format) the basic interaction of supply and demand and when the two change and shift which will indicate a time to buy or a time to sell.
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or www.renewableenergystocks.com
Research solar stocks and renewable energy stocks - over 1400 green stocks
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
Investors - sign up for free green stocks trading alerts and news http://www.investorideas.com/Resources/Newsletter.asp
Follow Renewable Energy Stocks onFacebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp , http://www.investorideas.com/About/News/Clientspecifics.asp
For more information contact Investor Ideas:
800 665 0411
Source: www.RenewableEnergyStocks.com, www.Investorideas.com
Solar Stocks Commentary with J Peter Lynch at Investorideas.com
Read other articles from Mr. Lynch, Exclusively at InvestorIdeas.com
http://www.investorideas.com/PL/
Current Portfolio Status
Since early March (3-6-2012) our solar portfolio has been out of the market and 100% in cash.
The total return of the 2012 portfolio has been a gain of 18.98% with a total holding time of 7 weeks. Once our indicators told us to exit our stocks, we moved quickly and sold our positions.
Remember that the HARDEST THING for investors to do is know when to sell. There is so much emotion, fear of missing out and general over all doubt. This is exactly why you have to set specific, non-emotional prices to exit if things do not go right. You cannot allow your emotions to get involved and take over your thinking.
Trust in your system and follow it regardless of what you think "should happen". Once you try to impose your will on your portfolio you will stop paying attention to what is most important - "what is" NOT what you think it should be.
General Market Comments - Red Flags Flying, move to the sidelines.
At this point the general market is what I would characterize as being in a RED FLAG environment in which I would move to the sidelines and wait for the market to run its course. In addition, we have entered the markets seasonably UNFAVORABLE season (May - Oct) which historically has been a terrible time to be invested. In addition, all of my technical indicators have signaled sell signals.
Keep in mind that there is NO WAY to know if this is the end of a short correction or the beginning of a longer market downtrend - all we can do is listen to our indicators and follow their lead. When we do that we eliminate "emotion" i.e. what we THINK should be happening from our investment equation and follow our time proven indicators that show us what is REALLY happening regardless of our opinion.
Solar Stocks Status
Since solar stocks as a whole have much higher volatility (beta) than the general markets we have seen then fall much further than the market in general - this is not unexpected and is the reason our indicators told us to exit ALL our solar stocks in early March 2012.
The industry and the solar marketplace are currently undergoing extreme turmoil with negatives everywhere and nothing positive in sight:
- Lower prices on solar panels than anyone had predicted
- Compressed margins, to the point that 90% of companies are losing money
- Worldwide finger pointing as to who is a fault
- Elimination of the very successful 1603 Treasury grant program, forcing the industry to fall back on Tax Equity - which adds two problems for the industry: there is not enough of it to handle demand and it adds a significant cost to large commercial solar projects.
- A growing number of solar companies around the world are going out of business generating all sorts of media comments that are really inaccurate and based on very little knowledge of how industries grow and develop overtime.
- All of these negatives have created investors #1 fear - uncertainty. Where growing uncertainty exists, investors do not come. As a result you can see from the table below that the industry has had a tough year and all stocks are STILL in down trends:
With all of these negatives and depressed stocks is there any good
news that investors can take to heart and maybe see the beginnings of a
light (sunlight) at the end of the tunnel?Well there are a couple of things we can look at and say that they may be the early beginnings of some good news and maybe the first sign of a buying opportunity:
- It is really hard to imagine that the news can get worse - so maybe good news will somehow fill the void.
- There is an old saying on Wall Street, attributed to Baron Rothschild - "The time to buy is when blood is running in the streets" - certainly a contrarian point of view and without question - the blood is running in the streets in the solar industry. But in the stock market when all of the selling is finished (after all the bad news is out) there is really nothing left but early buyers.
- After a number of years of downward movement - solar stocks are down an average of 76.66% since 2010 stocks tend to rebound and outperform and average year by close to 3 fold.
- Small positive changes are starting to show up. One of our solar stocks - CSIQ has had its recent price move above its 50 day moving average - a positive short term sign. A couple of the stocks now have positive monthly momentum - all of the others have negative momentum and mostly all have negative weekly momentum….
Background Analysis Notes
Keep in mind that there are two basic types of equity (stock) analysis. Below are a brief description of each and its primary purpose:
Fundamental Analysis - this is the analysis of the fundamental financial condition of a company to identify which stocks you may want to buy when the timing is right. This form of analysis will give you NO indication of the best time to buy a stock or sell a stock.
Technical Analysis - this form of analysis will tell you "when" to buy a stock and when to sell the stock. It will do this by showing you (in chart format) the basic interaction of supply and demand and when the two change and shift which will indicate a time to buy or a time to sell.
Mr. Lynch has worked, for 35 years as a Wall Street security analyst, an independent security analyst and private investor in small emerging technology
companies. He has been actively involved in following developments in
the renewable energy sector since 1977 and is regarded as an expert in
this field. He was the contributing editor for 17 years to the
Photovoltaic Insider Report, an early publication in PV that was
directed at industrial subscribers, such as major energy companies,
utilities and governments around the world. He is currently a private
investor and has from time to time been a financial/technology
consultant to a number of companies. He can be reached via e-mail at: SOLARJPL@aol.com. Please visit his website for the promotion of solar energy � www.sunseries.net.
About Investorideas.com - a leader in cleantech investor research Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or www.renewableenergystocks.com
Research solar stocks and renewable energy stocks - over 1400 green stocks
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
Investors - sign up for free green stocks trading alerts and news http://www.investorideas.com/Resources/Newsletter.asp
Follow Renewable Energy Stocks onFacebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp , http://www.investorideas.com/About/News/Clientspecifics.asp
For more information contact Investor Ideas:
800 665 0411
Source: www.RenewableEnergyStocks.com, www.Investorideas.com
Subscribe to:
Posts (Atom)